Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting Jul 25, 2022 08:00AM
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea Nov 26, 2021 08:00AM
Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis Nov 8, 2021 01:06PM
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis Oct 20, 2021 08:00AM
Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The International Liver Congress 2021 (EASL) Apr 16, 2021 01:23PM


Apr 6, 2021 08:00AM Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis
Mar 1, 2021 08:00AM Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)
Feb 8, 2021 08:00AM Enzychem Lifesciences Announces Poster Presentation At AACR Virtual Annual Meeting 2021
Jan 26, 2021 08:00AM Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space
Jan 8, 2021 03:03PM Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021
Aug 13, 2020 08:00AM Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia
Jul 13, 2020 08:00AM Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia
May 18, 2020 12:40PM Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug
May 14, 2020 12:35PM Enzychem Lifesciences Initiates Phase 2 Study for EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to Novel Coronavirus Pneumonia
May 1, 2020 01:36PM Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology
Apr 10, 2020 09:38AM Enzychem Lifesciences Announces Filing of U.S. Provisional Patent for EC-18 for the Treatment of COVID-19
Mar 17, 2020 11:23AM Enzychem Lifesciences Announces Plans to Advance Clinical Trial in South Korea for EC-18 as a Potential Therapeutic for COVID-19 Infection
Jan 28, 2020 09:00AM Enzychem Lifesciences Appoints Dr. Michael Charlton To Its Scientific Advisory Board
Nov 5, 2019 09:19AM Enzychem Lifesciences Announces Poster Presentation at Liver Meeting 2019